170 related articles for article (PubMed ID: 29556354)
1. Genes involved in prostate cancer progression determine MRI visibility.
Li P; You S; Nguyen C; Wang Y; Kim J; Sirohi D; Ziembiec A; Luthringer D; Lin SC; Daskivich T; Wu J; Freeman MR; Saouaf R; Li D; Kim HL
Theranostics; 2018; 8(7):1752-1765. PubMed ID: 29556354
[TBL] [Abstract][Full Text] [Related]
2. Histomic and transcriptomic features of MRI-visible and invisible clinically significant prostate cancers are associated with prognosis.
Lehto TK; Pylväläinen J; Sandeman K; Kenttämies A; Nordling S; Mills IG; Tang J; Mirtti T; Rannikko A
Int J Cancer; 2024 Mar; 154(5):926-939. PubMed ID: 37767987
[TBL] [Abstract][Full Text] [Related]
3. Association of multiparametric MRI quantitative imaging features with prostate cancer gene expression in MRI-targeted prostate biopsies.
Stoyanova R; Pollack A; Takhar M; Lynne C; Parra N; Lam LL; Alshalalfa M; Buerki C; Castillo R; Jorda M; Ashab HA; Kryvenko ON; Punnen S; Parekh DJ; Abramowitz MC; Gillies RJ; Davicioni E; Erho N; Ishkanian A
Oncotarget; 2016 Aug; 7(33):53362-53376. PubMed ID: 27438142
[TBL] [Abstract][Full Text] [Related]
4. Enhanced expression of centromere protein F predicts clinical progression and prognosis in patients with prostate cancer.
Zhuo YJ; Xi M; Wan YP; Hua W; Liu YL; Wan S; Zhou YL; Luo HW; Wu SL; Zhong WD; Wu CL
Int J Mol Med; 2015 Apr; 35(4):966-72. PubMed ID: 25647485
[TBL] [Abstract][Full Text] [Related]
5. miR-195 Inhibits Tumor Progression by Targeting RPS6KB1 in Human Prostate Cancer.
Cai C; Chen QB; Han ZD; Zhang YQ; He HC; Chen JH; Chen YR; Yang SB; Wu YD; Zeng YR; Qin GQ; Liang YX; Dai QS; Jiang FN; Wu SL; Zeng GH; Zhong WD; Wu CL
Clin Cancer Res; 2015 Nov; 21(21):4922-34. PubMed ID: 26080838
[TBL] [Abstract][Full Text] [Related]
6. Visibility of prostate cancer on transrectal ultrasound during fusion with multiparametric magnetic resonance imaging for biopsy.
van de Ven WJ; Sedelaar JP; van der Leest MM; Hulsbergen-van de Kaa CA; Barentsz JO; Fütterer JJ; Huisman HJ
Clin Imaging; 2016; 40(4):745-50. PubMed ID: 27317220
[TBL] [Abstract][Full Text] [Related]
7. Endorectal multiparametric MRI of the prostate: incremental effect of perfusion imaging on biopsy target identification.
Romero G; Foster BR; Pettersson DR; Fung AW; Guimaraes AR; Coakley FV
Clin Imaging; 2016; 40(3):553-7. PubMed ID: 27133703
[TBL] [Abstract][Full Text] [Related]
8. Association of quantitative magnetic resonance imaging parameters with histological findings from MRI/ultrasound fusion prostate biopsy.
Dianat SS; Carter HB; Schaeffer EM; Hamper UM; Epstein JI; Macura KJ
Can J Urol; 2015 Oct; 22(5):7965-72. PubMed ID: 26432966
[TBL] [Abstract][Full Text] [Related]
9. Low-risk prostate cancer patients without visible tumor (T1c) on multiparametric MRI could qualify for active surveillance candidate even if they did not meet inclusion criteria of active surveillance protocol.
Lee DH; Koo KC; Lee SH; Rha KH; Choi YD; Hong SJ; Chung BH
Jpn J Clin Oncol; 2013 May; 43(5):553-8. PubMed ID: 23580758
[TBL] [Abstract][Full Text] [Related]
10. Multicenter validation of prostate tumor localization using multiparametric MRI and prior knowledge.
Dinh CV; Steenbergen P; Ghobadi G; van der Poel H; Heijmink SW; de Jong J; Isebaert S; Haustermans K; Lerut E; Oyen R; Ou Y; Christos D; van der Heide UA
Med Phys; 2017 Mar; 44(3):949-961. PubMed ID: 28039927
[TBL] [Abstract][Full Text] [Related]
11. Multiparametric MRI in detection and staging of prostate cancer.
Boesen L
Dan Med J; 2017 Feb; 64(2):. PubMed ID: 28157066
[TBL] [Abstract][Full Text] [Related]
12. Biparametric 3T Magnetic Resonance Imaging for prostatic cancer detection in a biopsy-naïve patient population: a further improvement of PI-RADS v2?
Stanzione A; Imbriaco M; Cocozza S; Fusco F; Rusconi G; Nappi C; Mirone V; Mangiapia F; Brunetti A; Ragozzino A; Longo N
Eur J Radiol; 2016 Dec; 85(12):2269-2274. PubMed ID: 27842676
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Prostate Imaging Reporting and Data System versions 1 and 2 for the Detection of Peripheral Zone Gleason Score 3 + 4 = 7 Cancers.
Krishna S; McInnes M; Lim C; Lim R; Hakim SW; Flood TA; Schieda N
AJR Am J Roentgenol; 2017 Dec; 209(6):W365-W373. PubMed ID: 28981356
[TBL] [Abstract][Full Text] [Related]
14. What Is the Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in Excluding Prostate Cancer at Biopsy? A Systematic Review and Meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel.
Moldovan PC; Van den Broeck T; Sylvester R; Marconi L; Bellmunt J; van den Bergh RCN; Bolla M; Briers E; Cumberbatch MG; Fossati N; Gross T; Henry AM; Joniau S; van der Kwast TH; Matveev VB; van der Poel HG; De Santis M; Schoots IG; Wiegel T; Yuan CY; Cornford P; Mottet N; Lam TB; Rouvière O
Eur Urol; 2017 Aug; 72(2):250-266. PubMed ID: 28336078
[TBL] [Abstract][Full Text] [Related]
15. Multiparametric Magnetic Resonance Imaging Predicts Postoperative Pathology but Misses Aggressive Prostate Cancers as Assessed by Cell Cycle Progression Score.
Renard-Penna R; Cancel-Tassin G; Comperat E; Varinot J; Léon P; Roupret M; Mozer P; Vaessen C; Lucidarme O; Bitker MO; Cussenot O
J Urol; 2015 Dec; 194(6):1617-23. PubMed ID: 26272031
[TBL] [Abstract][Full Text] [Related]
16. Diffusion-weighted and dynamic contrast-enhanced MRI of prostate cancer: correlation of quantitative MR parameters with Gleason score and tumor angiogenesis.
Oto A; Yang C; Kayhan A; Tretiakova M; Antic T; Schmid-Tannwald C; Eggener S; Karczmar GS; Stadler WM
AJR Am J Roentgenol; 2011 Dec; 197(6):1382-90. PubMed ID: 22109293
[TBL] [Abstract][Full Text] [Related]
17. Toward an MRI-based nomogram for the prediction of transperineal prostate biopsy outcome: A physician and patient decision tool.
Lee SM; Liyanage SH; Wulaningsih W; Wolfe K; Carr T; Younis C; Van Hemelrijck M; Popert R; Acher P
Urol Oncol; 2017 Nov; 35(11):664.e11-664.e18. PubMed ID: 28801025
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic value of integrated PET/MRI for detection and localization of prostate cancer: Comparative study of multiparametric MRI and PET/CT.
Lee MS; Cho JY; Kim SY; Cheon GJ; Moon MH; Oh S; Lee J; Lee S; Woo S; Kim SH
J Magn Reson Imaging; 2017 Feb; 45(2):597-609. PubMed ID: 27586519
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of a cell-cycle progression score in men with prostate cancer managed with active surveillance after MRI-guided prostate biopsy--a pilot study.
Arsov C; Jankowiak F; Hiester A; Rabenalt R; Quentin M; Schimmöller L; Blondin D; Antoch G; Albers P
Anticancer Res; 2014 May; 34(5):2459-66. PubMed ID: 24778061
[TBL] [Abstract][Full Text] [Related]
20. Preoperative prediction of neurovascular bundle involvement of localized prostate cancer by combined T2 and diffusion-weighted imaging of magnetic resonance imaging, number of positive biopsy cores, and Gleason score.
Naiki T; Okamura T; Nagata D; Mori Y; Kawai N; Ogawa K; Akita H; Hashimoto Y; Tozawa K; Kohri K
Asian Pac J Cancer Prev; 2011; 12(4):909-13. PubMed ID: 21790224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
